Literature DB >> 2265458

Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters.

J M Jacquet1, F Bressolle, M Galtier, M Bourrier, D Donadio, J Jourdan, J F Rossi.   

Abstract

Doxorubicin was given by short i.v. infusion (dose range 25-72 mg/m2) to 18 patients who underwent three to seven successive courses of chemotherapy (total, 57 courses). Plasma levels of doxorubicin and its major metabolite doxorubicinol were determined by high-performance liquid chromatography over a 48-h period after the infusion. Pharmacokinetic parameters for the parent drug and its metabolite were calculated for each course of treatment. The results show considerable inter- and intraindividual variations for most parameters. The coefficients of variation (CV) ranged from 37% to 93% (inter-individual) and from 6% to 59% (intra-individual). Nevertheless, we observed a good stability over successive courses for terminal half-life in six patients (CV, 6%-25%) and for clearance and AUC in four subjects (CV, 10%-22%). The ratio of the AUCs for doxorubicinol: doxorubicin averaged 0.514. The pharmacokinetic pattern of doxorubicinol was biphasic in plasma of the majority of patients. We propose a model for curve-fitting of these metabolite plasma concentrations that is based on two successive releases of the compound in the plasma compartment, separated by a lag time.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2265458     DOI: 10.1007/bf00685716

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  22 in total

1.  Comparative pharmacokinetic study of adriamycin and 4'epi-adriamycin after their simultaneous intravenous administration.

Authors:  S Eksborg; U Stendahl; U Lönroth
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

2.  Clinical pharmacokinetics of adriamycin in hepatoma patients with cirrhosis.

Authors:  K K Chan; R T Chlebowski; M Tong; H S Chen; J F Gross; J R Bateman
Journal:  Cancer Res       Date:  1980-04       Impact factor: 12.701

3.  Intrahepatic and intravenous administration of adriamycin--a comparative pharmacokinetic study in patients with malignant liver tumours.

Authors:  S Eksborg; B J Cedermark; H S Strandler
Journal:  Med Oncol Tumor Pharmacother       Date:  1985

4.  Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols.

Authors:  R F Greene; J M Collins; J F Jenkins; J L Speyer; C E Myers
Journal:  Cancer Res       Date:  1983-07       Impact factor: 12.701

5.  Pharmacokinetics of doxorubicin in man: dose and schedule dependence.

Authors:  R Erttmann; N Erb; A Steinhoff; G Landbeck
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

6.  Distribution of adriamycin in cancer patients: tissue uptakes, plasma concentration after IV and hepatic IA administration.

Authors:  Y T Lee; K K Chan; P A Harris; J L Cohen
Journal:  Cancer       Date:  1980-05-01       Impact factor: 6.860

7.  Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.

Authors:  K Mross; P Maessen; W J van der Vijgh; H Gall; E Boven; H M Pinedo
Journal:  J Clin Oncol       Date:  1988-03       Impact factor: 44.544

8.  [Pharmacokinetic study of doxorubicin in the treatment of malignant non-Hodgkin's lymphomas].

Authors:  J Robert; P Vrignaud; A Iliadis; H Eghbali; B Hoerni
Journal:  Nouv Rev Fr Hematol       Date:  1983

9.  Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients.

Authors:  P A Speth; P C Linssen; J B Boezeman; H M Wessels; C Haanen
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

10.  A limited sampling procedure for estimating adriamycin pharmacokinetics in cancer patients.

Authors:  M C Launay; G Milano; A Iliadis; M Frenay; N Namer
Journal:  Br J Cancer       Date:  1989-07       Impact factor: 7.640

View more
  18 in total

1.  Pharmacokinetics and toxicity of idarubicin in the rat.

Authors:  O Kuhlmann; S Hofmann; M Weiss
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Oct-Dec       Impact factor: 2.441

2.  Doxorubicin pathways: pharmacodynamics and adverse effects.

Authors:  Caroline F Thorn; Connie Oshiro; Sharon Marsh; Tina Hernandez-Boussard; Howard McLeod; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-07       Impact factor: 2.089

Review 3.  Adaptive control methods for the dose individualisation of anticancer agents.

Authors:  A Rousseau; P Marquet; J Debord; C Sabot; G Lachâtre
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

4.  Doxorubicin and doxorubicinol plasma concentrations and excretion in parotid saliva.

Authors:  F Bressolle; J M Jacquet; M Galtier; J Jourdan; D Donadio; J F Rossi
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Prochlorperazine as a doxorubicin-efflux blocker: phase I clinical and pharmacokinetics studies.

Authors:  K S Sridhar; A Krishan; T S Samy; A Sauerteig; L L Wellham; G McPhee; R C Duncan; S Y Anac; B Ardalan; P W Benedetto
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Influence of the cardioprotective agent dexrazoxane on doxorubicin pharmacokinetics in the dog.

Authors:  J R Baldwin; B A Phillips; S K Overmyer; N Z Hatfield; P K Narang
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 7.  State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines.

Authors:  Charlene M Dawidczyk; Chloe Kim; Jea Ho Park; Luisa M Russell; Kwan Hyi Lee; Martin G Pomper; Peter C Searson
Journal:  J Control Release       Date:  2014-05-27       Impact factor: 9.776

8.  Pharmacokinetics of doxorubicin in pregnant women.

Authors:  Rachel J Ryu; Sara Eyal; Henry G Kaplan; Arezoo Akbarzadeh; Karen Hays; Kristin Puhl; Thomas R Easterling; Stacey L Berg; Kathleen A Scorsone; Eric M Feldman; Jason G Umans; Menachem Miodovnik; Mary F Hebert
Journal:  Cancer Chemother Pharmacol       Date:  2014-02-15       Impact factor: 3.333

9.  Bayesian estimation of doxorubicin pharmacokinetic parameters.

Authors:  F Bressolle; P Ray; J M Jacquet; J Brès; M Galtier; D Donadio; J Jourdan; J F Rossi
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

10.  Effects of genetic polymorphisms on the sulfation of doxorubicin by human SULT1C4 allozymes.

Authors:  Saud A Gohal; Mohammed I Rasool; Ahsan F Bairam; Eid S Alatwi; Fatemah A Alherz; Maryam S Abunnaja; Amal A El Daibani; Katsuhisa Kurogi; Ming-Cheh Liu
Journal:  J Biochem       Date:  2021-10-12       Impact factor: 3.387

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.